Published in J Clin Endocrinol Metab on May 01, 2001
Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci (2011) 1.74
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab (2007) 0.88
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J Lipid Res (2009) 0.87
Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II). J Lipid Res (2003) 0.77
Effect of functional sympathetic nervous system impairment of the liver and abdominal visceral adipose tissue on circulating triglyceride-rich lipoproteins. PLoS One (2017) 0.75
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 6.17
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (1992) 5.56
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab (2003) 3.10
Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma. Eur J Clin Invest (1975) 2.80
A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet (1999) 2.56
Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet (2000) 2.07
Multicentre evaluation of the DCA 2000 system for measuring glycated haemoglobin. DCA 2000 Study Group. Diabetes Metab (1997) 1.82
Role of viscous guar gums in lowering the glycemic response after a solid meal. Am J Clin Nutr (1994) 1.65
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem (1990) 1.46
Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem (2000) 1.45
REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. Arch Cardiovasc Dis (2008) 1.42
The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care (1996) 1.41
[SFC/ALFEDIAM (French Cardiology Society/French-speaking Association for the Study of Diabetes and Metabolic Diseases) guidelines on the management of the diabetic patient seen by a cardiologist. Recommendations, rationale, references]. Arch Mal Coeur Vaiss (2004) 1.41
Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res (1999) 1.40
Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis (2001) 1.39
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab (2004) 1.39
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
A preliminary multicentre study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamide-cyclosporin therapy. Diabet Med (1991) 1.39
Combined analysis of islet cell antibodies that cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in type I diabetic patients. Diabetes Care (1994) 1.38
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol (1995) 1.35
A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet (1999) 1.34
Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler Thromb Vasc Biol (1997) 1.32
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab (2008) 1.24
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) (2000) 1.15
Human zona pellucida glycoproteins and sperm binding: an urge for accurate nosology and nomenclature. Mol Hum Reprod (1998) 1.08
Increased triglyceride levels in shift workers. Am J Med (1992) 1.05
Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis (1989) 1.03
Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb (1994) 1.01
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. J Lipid Res (1996) 1.01
Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab (2000) 1.00
Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. J Lipid Res (1995) 0.98
The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis (1996) 0.98
Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens (1996) 0.97
Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res (1996) 0.96
Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab (1985) 0.96
Fulminant type 1 diabetes in Caucasians: A report of three cases. Diabetes Metab (2008) 0.96
Kinetic aspects of acetate metabolism in healthy humans using [1-13C] acetate. Am J Physiol (1996) 0.95
Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab (2004) 0.95
A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metabolism (2002) 0.94
Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. Circulation (1994) 0.94
Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. J Pharmacol Exp Ther (2005) 0.93
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med (2009) 0.93
[Diagnosis and classification of diabetes mellitus: the new criteria]. Diabetes Metab (1999) 0.92
Colonic fermentation from lactulose inhibits lipolysis in overweight subjects. Am J Physiol Endocrinol Metab (2005) 0.92
Glucose tolerance in viral hepatitis. A study of twenty patients during the acute phase and after recovery. Diabetes (1978) 0.90
Childhood obesity and insulin resistance in a Yucatan mini-piglet model: putative roles of IGF-1 and muscle PPARs in adipose tissue activity and development. Int J Obes (Lond) (2005) 0.90
Role of the kidney in regulating the metabolism of HDL in rabbits: evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry (2000) 0.90
High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Diabetologia (1997) 0.89
Recommendations regarding obesity surgery. Obes Surg (2005) 0.89
Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes. Int J Obes Relat Metab Disord (2002) 0.89
Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). Diabet Med (2009) 0.88
Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. Cancer Res (1992) 0.88
Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology (1993) 0.88
Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. Clin Chem (1993) 0.88
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab (2004) 0.88
Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis (1990) 0.88
Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men. Hum Genet (1993) 0.88
Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev (2000) 0.87
Production rate of acetate during colonic fermentation of lactulose: a stable-isotope study in humans. Am J Clin Nutr (1998) 0.87
Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM Study. Atherosclerosis (1996) 0.87
Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb (1993) 0.87
Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis (1989) 0.87
Effects of glutamine deprivation on protein synthesis in a model of human enterocytes in culture. Am J Physiol Gastrointest Liver Physiol (2001) 0.87
Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism. Arterioscler Thromb Vasc Biol (1997) 0.86
Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis (1991) 0.86
Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids. Am J Clin Nutr (1991) 0.86
The anti-proliferative and pro-apoptotic effects of the trans9, trans11 conjugated linoleic acid isomer on MCF-7 breast cancer cells are associated with LXR activation. Prostaglandins Leukot Essent Fatty Acids (2013) 0.86
Does the corticoadrenal adenoma with "pre-Cushing's syndrome" exist? J Nucl Med (1981) 0.85
Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J Lipid Res (2000) 0.85
Plasma vitamin A and E in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) adult diabetic patients. Int J Vitam Nutr Res (1991) 0.85
The international study of insulin and cancer. Lancet (2010) 0.85
Inter and intra individual variability of acute insulin response during intravenous glucose tolerance tests. Diabete Metab (1990) 0.85
Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem (1997) 0.85
Noninvasive tracing of human liver metabolism: comparison of phenylacetate and apoB-100 to sample glutamine. Am J Physiol (1999) 0.84
Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) (1981) 0.84